Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT

Aoyama,Mariko; Takizawa,Hiromitsu; Otani,Tamaki; Inoue,Seiya; Kawakita,Naoya; Tsuboi,Mitsuhiro; Bando,Yoshimi; Uehara,Hisanori; Kondo,Kazuya; Tangoku,Akira

doi:10.3892/or.2020.7720

Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT

Authors:
- Mariko Aoyama
- Hiromitsu Takizawa
- Tamaki Otani
- Seiya Inoue
- Naoya Kawakita
- Mitsuhiro Tsuboi
- Yoshimi Bando
- Hisanori Uehara
- Kazuya Kondo
- Akira Tangoku
View Affiliations

Affiliations: Department of Thoracic, Endocrine Surgery and Oncology, Institute of Health Biosciences, The University of Tokushima, Tokushima 770‑8503, Japan, Radioisotope Research Center, Tokushima University Graduate School, Tokushima 770‑8503, Japan, Department of Pathology, Tokushima University Hospital, Tokushima 770‑8503, Japan, Department of Oncological Medical Services, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770‑8503, Japan
Published online on: August 7, 2020 https://doi.org/10.3892/or.2020.7720
Pages: 1709-1716

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid carcinoma with a poor prognosis. Thus, suitable preclinical tumor models are required for the development of new ATC therapies. In the present study, orthotopic tumor xenograft models were established using ATC cell lines and SCID mice, and tumor invasion and the effects of anticancer drugs were evaluated using positron emission tomography/computed tomography (PET/CT) to repeatedly and non‑invasively monitor these models. Three ATC cell lines (8305c, 8505c, and ACT‑1) were used. Their sensitivities to two anticancer drugs (paclitaxel and lenvatinib) were investigated. The 8505c cell line was orthotopically implanted into SCID mice, which were then divided into three groups: No chemotherapy, paclitaxel (5 mg/kg, administered intraperitoneally, every week), and lenvatinib (5 mg/kg, oral route, every day) groups. PET/CT was performed and tumor growth and the effects of anticancer drugs based on tumor volume and fludeoxyglucose (FDG) uptake were evaluated. 8505c cells exhibited the highest sensitivity to the anticancer drugs. In mice implanted with 8505c cells, continuous increases in FDG uptake associated with tumor growth were detected on PET/CT in the group that received no chemotherapy. The tumor volume and FDG uptake increased by 91.5‑ and 2.4‑fold, respectively, within 2 weeks. The increase observed in tumor volume was 26.9‑ and 12.2‑fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. Furthermore, the increase in FDG uptake was 1.8 and 1.6‑fold in the paclitaxel and lenvatinib groups, respectively, within 2 weeks. In our orthotopic SCID mouse model, tumor growth and the effects of anticancer drugs were repeatedly and non‑invasively monitored using PET/CT. The present method is useful for the development of new ATC treatments.

View Figures

View References

1	Kebebew E, Dreenspan FS, Clark OH, Woeber KA and McMillan A: Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 103:1330–1335. 2005. View Article : Google Scholar : PubMed/NCBI
2	Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, Hjelm Skog AL and Wallin G: Anaplastic thyroid carcinoma: Three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 12:1848–1853. 2002. View Article : Google Scholar
3	Sugitani I, Onoda N, Ito K and Sugitabi S: Management of anaplastic thyroid carcinoma: Fruits from ATC Research Consortium of Japan. J Nippon Med Sch. 85:18–27. 2018. View Article : Google Scholar : PubMed/NCBI
4	Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH and DeConti R: A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advancer thyroid carcinoma. Cancer. 56:2155–2160. 1985. View Article : Google Scholar : PubMed/NCBI
5	Ahuja S and Emst H: Chemotherapy of thyroid carcinoma. J Endocrinol Invest. 3:303–310. 1987. View Article : Google Scholar
6	Ain KB, Egorin MJ and DeSimone PA: Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion. Collaborative Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid. 10:587–594. 2000. View Article : Google Scholar : PubMed/NCBI
7	Onoda N, Sugino K, Higashiyama T, Kammor i, Toda K, Ito K, Yoshida A, Suganuma N, Nakashima N, Suzuki S, et al: The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: A nationwide prospective study. Thyroid. 26:1293–1299. 2016. View Article : Google Scholar : PubMed/NCBI
8	Tahara M, Kiyota N, Yamazaki T, Chayara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, et al: Lenvatinib for anaplastic thyroid cancer. Front Oncol. 7:252017. View Article : Google Scholar : PubMed/NCBI
9	Hundahl SA, Fleming ID, Fremgen AM and Menck HR: A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 83:2638–2648. 1998. View Article : Google Scholar : PubMed/NCBI
10	Kitamura Y, Shimizu K, Hagahama M, Sugino K, Osaki O, Mimura T, Ito K, Ito K and Tanaka S: Immediate causes of death in thyroid carcinoma: Clinicopathological analysis of 161 fetal cases. J Clin Endocrinol Metab. 84:4034–4039. 1999. View Article : Google Scholar
11	Kim S, Park YW, Schiff BA, Doan DD, Yazici Y, Jasser SA, Younes M, Mandal M, Bekele BN and Myers JN: An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res. 11:1713–1721. 2005. View Article : Google Scholar : PubMed/NCBI
12	Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V and Parangi S: A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid. 19:1077–1084. 2009. View Article : Google Scholar : PubMed/NCBI
13	Sewell W, Reeb A and Lin RY: An orthotopic mouse model of anaplastic thyroid carcinoma. J Vis Exp. 74:500972013.
14	Paget S: The distribution of secondary growths in cancer of the breast. Lancet. 133:571–573. 1889. View Article : Google Scholar
15	Bibby MC: Orthotopic models of cancer for preclinical drug evaluation: Advantages and disadvantages. Eur J Cancer. 40:852–857. 2004. View Article : Google Scholar : PubMed/NCBI
16	Nehas MA, Nucera C, Nagarkatti SS, Sado w, Morales-Garcia D, Hodin RA and Parangi S: Late intervention with anti-BRAFV600E therapy induces tumor regression in an orthotopic mouse model of anaplastic thyroid cancer. Endocrinology. 153:985–994. 2012. View Article : Google Scholar : PubMed/NCBI
17	Cha W, Kim DW, Kim SD, Jeon EH, Jeong WJ and Ahn SH: Effect of perioperative treatment with a hypoxia-inducible factor-1-alpha inhibitor in an orthotopic surgical mouse models of thyroid cancer. Anticancer Res. 35:2049–2054. 2015.PubMed/NCBI
18	Nehs MA, Nagarkatti S, Nucera C, Hodin RA and Parangi S: Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse models of anaplastic thyroid cancer. Surgery. 148:1154–1162. 2010. View Article : Google Scholar : PubMed/NCBI
19	Mokhtar M, Kondo K, Takizawa H, Ohtani T, Otsuka H, Kubo H, Kajiura K, Nakagawa Y, Kawanaka Y, Yoshida M, et al: Non-invasive monitoring of anticancer effects of cisplatin on lung cancer in an orthotopic SICD mouse model using [18F] FDG PET-CT. Oncol Rep. 31:2007–2014. 2014. View Article : Google Scholar : PubMed/NCBI
20	Otani T, Kondo K, Takizawa H, Kajiura K, Fujino H, Otsuka H and Miyoshi H: Non-invasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDG-PET/CT and CT. Oncol Rep. 41:447–454. 2019.PubMed/NCBI
21	Marcus C, Whitworth PW, Surasi DS, Pai SI and Subramaniam RM: PET/CT in the Management of thyroid cancers. AJR Am J Roentgenol. 202:1316–1329. 2014. View Article : Google Scholar : PubMed/NCBI
22	Poisson T, Deandreis D, Leboulleux S, Bidault F, Bonniaud G, Baillot S, Auperin A, AI Ghuzlan A, Travagli JP and Lumbroso J: 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging. 37:2277–2285. 2010. View Article : Google Scholar : PubMed/NCBI
23	Killkenny C, Browne WJ, Cuthill IC, Emerson M and Altman DG: Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. Osteoarthritis Cartilage. 20:256–260. 2012. View Article : Google Scholar : PubMed/NCBI
24	Jing C, Gao Z, Wang R, Yang Z, Shi B and Hou P: Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Am J Cancer Res. 4:903–912. 2017.
25	Ahmed S, Ghazarian MP, Cabanillas ME, Zafereo ME, Williams MD, Vu T, Schomer DF and Debnam JM: Imaging of anaplastic thyroid carcinoma. AJNR AM J Neuroradiol. 3:547–551. 2018. View Article : Google Scholar
26	Deeken-Draisey A, Yang GY, Gao J and Alexiev BA: Anaplastic thyroid carcinoma: An epidemiologic, histologic, immunohistochemical, and molecular single-institution study. Hum Pathol. 82:140–148. 2018. View Article : Google Scholar : PubMed/NCBI
27	Kostakoglu L and Chauvie S: Metabolic tumor volume metrics in lymphoma. Semin Nucl Med. 48:50–66. 2018. View Article : Google Scholar : PubMed/NCBI
28	Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF and Subramaniam RM: 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: Adding value to clinical staging. J Nucl Med. 53:709–715. 2012. View Article : Google Scholar : PubMed/NCBI
29	Manohar PM, Beesley LJ, Bellile EL, Worden FP and Avram AM: Prognostic value of FDG-PET/CT metabolic parameters in metastatic radioiodine-refractory differentiated thyroid cancer. Clin Nucl Med. 43:641–647. 2018. View Article : Google Scholar : PubMed/NCBI
30	Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M and Funahashi Y: Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014:132014. View Article : Google Scholar
31	Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkiier T, Cella D and Davidson NA: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 26:2666–2676. 2007. View Article : Google Scholar